MOBERG DERMA’S PUBLIC OFFER OVERSUBSCRIBED – trading on the NASDAQ OMX Stockholm will start on 26 May
The public offer to acquire shares in Moberg Derma AB (publ) attracted large interest and the offer was oversubscribed. Through this new share issue Moberg Derma has raised SEK 74 million before issue expenses. May 26th, 2011 will be the first day of trading on the main market of NASDAQ OMX Stockholm (Ticker symbol: MOB). The Board of Moberg Derma has taken a decision on the allotment of shares.
“There has been large interest from investors. It is particularly pleasing that so many investors have appreciated our focus on innovative development based on proven compounds and the value of having products on the market,” comments Peter Wolpert, CEO of Moberg Derma, who continues:
“The additional capital raised enables us to develop our pharmaceutical projects to commercialization, while also providing strong support to the international commercialisation of our products. We look forward to continuing Moberg Derma’s growth and expansion.”
Once the share offer has been implemented, in line with the prospectus published on 2 May 2011, the total number of shares in Moberg Derma will number 9,080,220. The offer relates to a total of 2,551,724 new shares, representing 28 percent of the capital and votes in Moberg Derma once the issue is completed. The total value of the share offer is SEK 74 million. On completion of the share offer, the number of shareholders will exceed 800, with private investors owning approximately half of the shares in Moberg Derma and institutional investors owning the remaining shares. May 26th, 2011 will be the first day of trading on the main market of NASDAQ OMX Stockholm (Ticker symbol: MOB).
Avanza Bank AB has been Moberg Derma’s financial advisor for this share offer and Västra Hamnen Fondkommission AB has been responsible for sales to institutional investors.
For further information, contact:
Peter Wolpert, CEO
Mobile: +46 70-735 71 35
E-mail: peter.wolpert@mobergderma.se
Magnus Persson, IR
Mobile: +46 73-355 26 01
E-mail: magnus.persson@mobergderma.se
About Moberg Derma
Moberg Derma AB (publ.), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers approved and launched products to projects in the preclinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006. For further information, please visit: www.mobergderma.se
Tags: